1. Home
  2. Directory
  3. New York
  4. Rochester
  5. Student In An Organized Health Care Education Training Program
  6. NPI Profile
  7. Prescriptions 1932789310

JONATHAN EDWARD NUTT
Prescription History 1932789310
Student in an Organized Health Care Education/Training Program in Rochester, NY

NPI Status: Active since April 10, 2021

Contact Information

601 ELMWOOD AVE
ROCHESTER, NY
ZIP 14642
Phone: (585) 756-4800

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JONATHAN EDWARD NUTT, an active Student in an Organized Health Care Education/Training Program specialist practicing in Rochester, NY. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 123 documented patient claims. Among these therapy options, the most frequently utilized medication is Levetiracetam, which accounts for 68 claims alone.

Medication Index

A
L
S
Z
No matching medications currently found on file.

Aimovig Autoinjector

Generic Formulation: Erenumab-AooeSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 540
NY State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills41.5
Peer Average Days Supply1,230
Conservative Utilization

This provider writes prescriptions for this formulation 48.6% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $14,249.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$791.62

State Avg Cost Per Claim

$872.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to help prevent migraine. This medication may work by changing the amounts of certain natural substances in the brain. Erenumab belongs to a class of drugs known as monoclonal antibodies. Preventing frequent migraine attacks can help improve your ability to concentrate and do your usual tasks.

Levetiracetam

Generic Formulation: LevetiracetamSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 68
30-Day Fills 97.9
Days Supply 2,938
NY State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills70.3
Peer Average Days Supply1,936
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 33.3% more claims than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,911.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$57.53

State Avg Cost Per Claim

$37.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.

Therapeutic Applications

Levetiracetam is used to treat seizures (epilepsy). It belongs to a class of drugs known as anticonvulsants. Levetiracetam may decrease the number of seizures you have.

Sumatriptan Succinate

Generic Formulation: Sumatriptan SuccinateSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 335
NY State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills26.8
Peer Average Days Supply708
Conservative Utilization

This provider writes prescriptions for this formulation 47.8% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $109.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.10

State Avg Cost Per Claim

$50.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.

Therapeutic Applications

Sumatriptan is used to treat migraines and cluster headaches. It helps to relieve pain and other symptoms of migraines/headaches including sensitivity to light or sound, nausea, and vomiting. Prompt treatment allows you to get back to your normal routine and may decrease your need for other pain medications. It does not prevent future migraines/headaches or reduce how often you may get a headache. Sumatriptan belongs to a group of drugs called triptans. It affects a certain natural chemical (serotonin) that constricts blood vessels in the brain. It may also block other pain pathways in the brain.

Zonisamide

Generic Formulation: ZonisamideSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 25
30-Day Fills 25.0
Days Supply 727
NY State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills45.0
Peer Average Days Supply1,304
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,070.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$42.84

State Avg Cost Per Claim

$40.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.

Therapeutic Applications

Zonisamide is used with other medications to prevent and control seizures (epilepsy). Zonisamide is a sulfonamide anticonvulsant and a carbonic anhydrase inhibitor. It is unknown how zonisamide works to prevent seizures.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JONATHAN EDWARD NUTT provides transparency into local medical care patterns within Rochester, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Student in an Organized Health Care Education/Training Program** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.